Claritev Corp SEC Filings

Claritev Corp (CTEV) senior vice president and general counsel reported a small open-market purchase of company stock. On 11/17/2025, the officer acquired 625 shares of Class A common stock at a price of $38.8364 per share, according to a Form 4 filing. Following this transaction, the officer beneficially owns 25,028 shares of Claritev Class A common stock, held directly.

Claritev Corp (CTEV): Hellman & Friedman–affiliated reporting persons disclosed open‑market disposals of Class A common stock tied to an underwritten public offering on 11/12/2025. The shares were sold at a price per share equal to the public offering price, net of underwriting discounts and commissions.

Reported transactions included, for example, a sale of 789,936 shares at $48.6675 per share and additional sales by affiliated funds on the same date. Following the transactions, each affiliated entity reported updated indirect beneficial holdings. The filing identifies the reporting persons as affiliated with Hellman & Friedman funds and indicates indirect ownership across multiple vehicles.

Hellman & Friedman–affiliated funds filed Amendment No. 3 to Schedule 13D on Claritev Corporation (CTEV), reporting aggregate beneficial ownership of 3,887,858 shares, or 23.5% of Class A common stock. The percentage is based on 16,525,644 shares outstanding as of November 3, 2025.

The filing discloses a secondary sale by H&F selling stockholders of 1,500,000 shares at a $51.50 public offering price per share, less a $2.8325 underwriting discount, with an underwriters’ overallotment option for up to 225,000 shares. A 60‑day lock‑up from November 12, 2025 applies to the issuer, directors, officers, the H&F selling stockholders, and others, subject to exceptions.

If the overallotment is exercised, the filing notes beneficial ownership would be 3,662,858 shares, or 22.2%. The funds state investment intent and may buy or sell securities over time, subject to market conditions and agreements referenced.

Claritev Corporation disclosed that affiliates of Hellman & Friedman sold 1,500,000 shares of its Class A common stock in an underwritten secondary offering at $51.50 per share. The Company did not sell any shares and received no proceeds from this transaction.

The Selling Stockholders granted the underwriters a 30-day option to purchase up to 225,000 additional shares. Barclays Capital, Guggenheim Securities, and Wells Fargo Securities acted as joint bookrunners. The offering closed on November 14, 2025. The agreement includes customary representations, warranties, conditions, termination provisions, and indemnification.

Claritev Corporation is registering 1,500,000 shares of its Class A common stock for resale by existing selling securityholders, with underwriters holding an option to purchase up to an additional 225,000 shares. All shares are being sold by current owners, so Claritev will not receive proceeds, though it will cover offering expenses other than underwriting discounts and commissions.

As of September 30, 2025, 16,509,496 shares of Class A common stock were outstanding. The H&F Investors group, which controlled approximately 32.6% of Claritev’s voting equity before this offering, will beneficially own about 23.5% after the base deal, or 22.2% if the underwriters’ option is fully exercised.

Claritev provides data-driven cost management solutions to healthcare payors. Its analytics, network, payment integrity and data science services target lower medical costs and better reimbursement accuracy, and identified approximately $18.6 billion in potential medical cost savings for the nine months ended September 30, 2025.

Claritev Corporation reported Q3 2025 results with revenue of $245,959 thousand, up from $230,495 thousand a year ago. Operating income was $10,067 thousand versus an operating loss last year, while net loss narrowed to $69,753 thousand from $391,450 thousand. Net loss per share was $4.23, adjusted for the 1-for-40 reverse split.

For the first nine months, revenue reached $718,859 thousand versus $698,479 thousand, with operating income of $36,387 thousand and a net loss of $203,712 thousand. Year-to-date operating cash flow was $51,038 thousand. Cash and cash equivalents were $39,152 thousand, plus $11,493 thousand of restricted cash, as of September 30, 2025. Long-term debt (net) was $4,546,671 thousand and shareholders’ deficit was $101,835 thousand. The company completed a January 30, 2025 refinancing, established a $350,000 thousand revolving credit facility (with $70,000 thousand outstanding at quarter end), and recorded interest expense of $101,232 thousand in Q3.

Claritev Corporation furnished a Form 8-K to announce it issued a press release reporting financial results for the third quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference.

The information under Item 2.02, including Exhibit 99.1, is furnished and not filed under the Exchange Act and is not subject to Section 18 liability. The filing also lists Exhibit 104 for the cover page Inline XBRL data.

Claritev Corporation renewed contracts with its ten largest clients during 2025, a group that represented approximately 70% of total 2024 revenues. The renewals include automatically renewing agreements that were each renewed for one year.

Excluding clients with automatic one-year renewals, these largest clients accounted for approximately 57% of 2024 revenues. Within this group, the weighted average contract term is greater than three years, excluding the one-year automatic renewals. Claritev highlights continued focus on affordability, transparency, and quality through technology and AI across its enterprise platform.

Claritev Corp (CTEV) insider filing: the SVP, Chief Growth Officer reported a Form 4 for an RSU vesting event on 10/14/2025. The filing shows 7,684 Class A shares were withheld to cover taxes (Code F) at $55.26 per share, a non‑open‑market transaction tied to restricted stock unit vesting. Following this tax withholding, the officer directly holds 107,891 Class A shares.